›Minor criteria (>/= 3 of 9 warrants ICU): RR >/= 30/min, PaO2/FiO2 < 250, multilobar infiltrates, confusion, BUN >/= 7 mmol/L, WBC < 4 x 10^9/L, platelets < 100 x 10^9/L, hypothermia < 36°C, hypotension requiring aggressive resuscitation
›AJRCCM 2021 ATS Clinical Practice Guideline [4]
Hemodynamic Monitoring
›Hemodynamic targets and monitoring
›SBP >/= 90 mmHg; MAP >/= 65 mmHg in septic shock
›HR < 100/min as stability indicator
›Continuous pulse oximetry and cardiac monitoring
›Vasopressor initiation (norepinephrine first-line) for septic shock refractory to 30 mL/kg IV fluid bolus
Critical Pitfalls
›Early recognition pitfalls in viral pneumonia
›Clinical features alone cannot reliably distinguish viral from bacterial pneumonia; do not withhold empiric antibiotics in severely ill patients pending pathogen identification
›Rapid deterioration to ARDS possible with influenza H1N1, COVID-19, and adenovirus type 14 — reassess frequently
›Secondary bacterial superinfection (especially S. aureus) with influenza can cause rapid clinical decline despite antiviral treatment
02History/hx39
Symptom Onset and Character
›Typical viral pneumonia presentation
›Gradual onset of dry cough over days (versus abrupt onset in bacterial pneumonia)
›VTE prophylaxis: enoxaparin 40 mg SC daily (GFR > 30); unfractionated heparin 5000 units SC TID if GFR < 30
›Nutritional support: high-protein 1.2-1.5 g/kg/day; energy 25-30 kcal/kg/day for malnourished patients
›Int J Environ Res Public Health 2019 [10]
›Antibiotic use and stewardship
›Defer antibiotics if confirmed viral etiology with procalcitonin </= 0.25 ng/mL and low suspicion for bacterial coinfection
›If bacterial coinfection cannot be excluded, treat empirically per ATS/IDSA CAP guidelines (beta-lactam plus macrolide or respiratory fluoroquinolone)
›Each additional antibiotic day increases resistant organism risk by approximately 7%; JAMA 2024 [9]
›De-escalate with serial procalcitonin monitoring
09Special Populations/sp48
Pregnancy
›Pregnancy-specific considerations in viral pneumonia
›Physiologic changes
›Elevated diaphragm reduces functional residual capacity; hypoxemia develops more rapidly
›Increased oxygen consumption and minute ventilation
›Immunologic shift toward Th2 response increases susceptibility to viral pneumonia
›Severity and outcomes
›Pregnancy significantly increases risk of severe influenza and COVID-19 requiring ICU admission
›Third trimester at highest risk for respiratory failure
›SpO2 target >/= 95% in pregnancy (versus 92% in non-pregnant adults)
›Treatment modifications
›Oseltamivir: safe in all trimesters; no dose adjustment required
›Remdesivir: limited human pregnancy data; use if benefit outweighs risk
›Dexamethasone 6 mg daily: use for COVID-19 requiring O2; may accelerate fetal lung maturity if < 34 weeks
›Zanamivir inhaled: preferred by some guidelines over oseltamivir in first trimester due to limited systemic absorption
›Acyclovir IV: safe in pregnancy for varicella pneumonia
›Early obstetrics consultation for gestational assessment and fetal monitoring
Geriatric
›Geriatric-specific considerations
›Atypical presentations
›Absence of fever or minimally elevated temperature is common in elderly
›Falls, delirium, or functional decline may be the presenting complaint
›Tachypnea may be the most sensitive early finding
›Severity and risk
›Age >/= 65 years is a CURB-65 point and independent mortality predictor
›Frailty and nutritional status independently worsen outcomes
›Higher rates of bacterial superinfection and complications
›Treatment considerations
›Oseltamivir: standard dosing; reduce to 75 mg once daily if GFR < 30 mL/min/1.73m2
›Renal function must guide all antiviral and antibiotic dosing
›Early nutritional intervention reduces pneumonia readmission by up to 77% in malnourished older adults
›Int J Environ Res Public Health 2019 [10]
Pediatrics
›Pediatric-specific considerations in viral pneumonia
›Epidemiology and etiology
›RSV is the most common cause of lower respiratory tract infection in children < 2 years
›Influenza, parainfluenza, adenovirus, and hMPV are next most common
›Rhinovirus frequently implicated in wheezing-associated respiratory illness in children
›Severity assessment
›Tachypnea by age: > 60/min (< 2 months), > 50/min (2-12 months), > 40/min (1-5 years), > 30/min (> 5 years) per WHO criteria
›Retractions, nasal flaring, grunting: signs of severe respiratory distress in infants
›SpO2 < 90% indicates need for supplemental oxygen and hospitalization consideration
›PIDS/IDSA Pediatric CAP Guideline 2011 [7]
›Treatment modifications
›Oseltamivir dosing by weight (children >/= 1 year):
›< 15 kg: 30 mg PO BID x 5 days
›15-23 kg: 45 mg PO BID x 5 days
›23-40 kg: 60 mg PO BID x 5 days
›> 40 kg: 75 mg PO BID x 5 days (adult dose)
›RSV: palivizumab prophylaxis for high-risk infants; supportive care for acute illness
›Avoid aspirin in children with suspected viral illness (Reye syndrome risk)
10Background/b50
Epidemiology
›Viral pneumonia epidemiology data
›Viral pneumonia accounts for up to 40% of community-acquired pneumonia cases with an identified pathogen
›Influenza, rhinovirus, and SARS-CoV-2 are the most common etiologies in adults
›RSV is the leading viral cause of lower respiratory infection in children < 5 years worldwide
›JAMA 2024 [9]
›Mortality and morbidity rates
›CAP is the leading infectious cause of death in the United States
›30-day mortality: 1-5% outpatient, 5-15% hospitalized, up to 40% ICU-admitted patients
›Influenza pneumonia mortality in hospitalized adults: approximately 5-10%
›COVID-19 pneumonia ICU mortality: 20-40% depending on variant and vaccination status
›Lancet 2025 [5]
›Seasonal and geographic patterns
›Influenza epidemics occur annually during winter months in temperate climates
›RSV peaks October through March in northern hemisphere
›COVID-19 has year-round circulation with seasonal surges
Pathophysiology
›Viral pneumonia pathophysiology
›Primary viral injury mechanism
›Direct cytopathic effect on pneumocytes type I and II, causing alveolar barrier disruption
›Viral replication in upper and lower respiratory epithelium triggers innate immune response
›Type I interferon response (IFN-alpha, IFN-beta) limits early viral spread
›Inflammatory cascade
›Macrophage activation and cytokine release (IL-6, IL-1-beta, TNF-alpha, IL-8)
›Cytokine storm in severe COVID-19 and severe influenza contributes to ARDS
›Lymphopenia is characteristic: CD4+ and CD8+ T-cell depletion in severe viral pneumonia
›Structural consequences
›Alveolar flooding from protein-rich edema fluid impairs gas exchange
›Bilateral interstitial pattern on imaging reflects diffuse alveolar involvement
›Secondary bacterial superinfection facilitated by viral disruption of mucociliary clearance and innate defense
›Lancet 2011 [2]
›ARDS progression
›Berlin Definition: PaO2/FiO2 < 300 mmHg with bilateral opacities not fully explained by effusion or collapse, within 1 week of insult
›Antivirals most effective when initiated early; oseltamivir reduces hospitalization duration by approximately 1 day when started within 48 hours
›In severe or ICU-level illness, antiviral therapy is beneficial regardless of symptom duration
›ERS/ESICM/ESCMID/ALAT 2023 [6]
›Corticosteroid evidence
›Dexamethasone 6 mg/day x 10 days reduces mortality in COVID-19 requiring O2 (NNT approximately 8 for ventilated patients; NNT approximately 25 for patients on O2 alone)
›Corticosteroids not routinely recommended for non-COVID viral pneumonia; may worsen outcomes
›Corticosteroids within 24 hours may reduce 28-day mortality in severe bacterial CAP coinfection
›Antibiotic stewardship
›Procalcitonin-guided antibiotic discontinuation reduces antibiotic days without increase in mortality
›Procalcitonin NPV for bacterial pneumonia is > 95% when level < 0.1 ng/mL
›JAMA 2024 [9]
›Lung-protective ventilation for ARDS
›Tidal volume 6 mL/kg predicted body weight
›Plateau pressure < 30 cmH2O
›PEEP titrated to oxygenation; high PEEP strategy for moderate-severe ARDS
›Prone positioning for PaO2/FiO2 < 150 mmHg; reduces mortality by 16% (Class I recommendation)
11Patient Discharge Instructions/pdi15
copy discharge instructions
›Discharge instructions for viral pneumonia
›Medications: take all prescribed antivirals (e.g., oseltamivir) for the full course even if you feel better
›Activity: rest and avoid strenuous activity until fever has resolved for at least 24 hours
›Nutrition and hydration: drink plenty of fluids; small frequent meals if appetite is poor
›Isolation: stay home from work, school, or public places for at least 24 hours after fever resolves without antipyretics; use respiratory etiquette (cover coughs/sneezes, hand hygiene)
›Return-to-ER red flags: return immediately if any of the following occur
›Worsening shortness of breath or inability to breathe comfortably at rest
›Persistent or worsening fever greater than 38.5°C beyond 72 hours despite treatment
›Chest pain, lightheadedness, fainting, or palpitations
›New confusion, difficulty thinking clearly, or unusual drowsiness
›Inability to keep down fluids or medications
›Coughing up blood or large amounts of discolored sputum
›Blue or purple discoloration of lips or fingertips (cyanosis)
›Follow-up: see your family doctor within 48-72 hours; a repeat chest X-ray at 6-8 weeks is recommended for patients over 50 years or with smoking history to exclude underlying lung pathology
›Prevention: annual influenza vaccination; COVID-19 vaccination per current schedule; pneumococcal vaccination per age/risk guidelines; hand hygiene and respiratory etiquette
12References/r23
Guidelines and Key Sources
›ATS/IDSA CAP Clinical Practice Guideline 2019
›Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults With Community-Acquired Pneumonia. AJRCCM 2019. PMID: PMC6812437
›Site-of-care decisions, antibiotic recommendations, and severity criteria
›ATS Clinical Practice Guideline - Viral Testing 2021
›Evans SE, Jennerich AL, Azar MM, et al. Nucleic Acid-Based Testing for Noninfluenza Viral Pathogens in Adults With Suspected Community-Acquired Pneumonia. AJRCCM 2021. PMC8314899
›Recommends multiplex PCR panels for hospitalized CAP patients when viral etiology possible
›ERS/ESICM/ESCMID/ALAT Severe CAP Guideline 2023
›Martin-Loeches I, Torres A, Nagavci B, et al. European Respiratory Journal 2023. PMID: 37012080
›Oseltamivir first-line for severe influenza pneumonia; antiviral regardless of duration in ICU patients
Landmark Reviews and Studies
›Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral Pneumonia. Lancet 2011. PMID: 21435708
›Comprehensive review of viral pneumonia epidemiology, pathophysiology, and management
›Documents that clinical features alone cannot reliably distinguish viral from bacterial etiology
›Vaughn VM, Dickson RP, Horowitz JK, Flanders SA. Community-Acquired Pneumonia: A Review. JAMA 2024
›Viral pneumonia accounts for up to 40% of CAP with identified pathogen; influenza, rhinovirus, SARS-CoV-2 most common
›Procalcitonin-guided antibiotic stewardship supported for CAP management
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.